top of page

THE NEXT-GENERATION OF PCR

PCR Hyperplexed without compromise

Our Hyperplex PCR (hpPCR™) technology enables detection of up to 100 markers in a single sample with highly specific and ultra-sensitive performance.

VISION

The ultimate diagnostic solution, available to everyone

We strongly believe in a future where advanced molecular testing is available to everyone. Our technology enables unparallelled degree of insights using simple routine workflows. Thanks to our novel nano- & biochemistry, this is achieved without the need for complex instrumentation, meaning that any lab can get started without large up-front costs.

Nanopixel hpPCR.jpeg

Hyperplex PCR (hpPCR)

PCR has long been the go-to molecular testing method providing scalability and highly sensitive results. However, it may become impractical or costly for high-throughput projects where broad genomic insight is required, or when there is a need to detect difficult, numerous target sequences in a single sample.


In comparison, NGS approaches excel in discovering novel genes and provide extreme sequence specificity. Yet, the initial equipment costs, ongoing reagent expenses, service fees, training required and turnaround time to results present significant barriers for many labs.

We introduce the next-generation of PCR with ultra-sensitivity, specificity and hyperplexing. The hpPCR assay enables single molecule detection of up to 100 pathogens/variants in a single tube eliminating the need for sequencing. Results can be achieved within 4h.

 

Sensitivity, specificity, multiplexity.
No compromises.

Multiplexing_hi_dark.png

WHY APLEX BIO

Full molecular snapshot of any biological sample

Today only a fraction of information is collected from patient samples. Our vision is to allow all information to be precisely collected, every time.

 

No more delays in diagnostics. No more bias.

INDUSTRY

Our Partners

Our partners involved in supporting us on our journey.

Partner_Scilife_white.png
Partner_EIT_white.png
Partner_KIAB_white.png

News

Latest from
APLEX Bio

APLEX Bio recognized as top Swedish innovation on the IVA-100 list for 2023

10 maj 2023

APLEX Bio recognized as impact company by EQT Foundation

11 dec. 2022

hpPCR used in long-term SARS-CoV-2 surveillance study

26 nov. 2022

bottom of page